Latest Drugs, Latest Approval in CD30 monoclonal antibodies

What are CD30 monoclonal antibodies?

Monoclonal antibodies used in immunotherapy are produced artificially from a cell clone therefore consist of a single type of immunoglobulin. They are targeted towards specific antigens and bind to the antigens to form a complex. The complex can be recognized and destroyed by phagocytes or used for other diagnostic purposes. CD30 has been identified as a marker on Reed–Sternberg cells in Hodgkin lymphoma and cells in other specific types of lymphoma. CD30 monoclonal antibodies may be used to treat Hodgkin's lymphoma or anaplastic large cell lymphoma.

Name Updated
Brentuximab vedotin (Brentuximab vedotin [ bren-tux-i-mab-ve-doe-tin ]) 15-Aug-2023
Adcetris (Brentuximab vedotin [ bren-tux-i-mab-ve-doe-tin ]) 05-Aug-2023